Taysha Gene Therapies gears up to approach regulators with a new candidate for a debilitating neurodegenerative disease
After launching early last year, Taysha Gene Therapies quickly went about checking off key milestones. Within five months, it pulled in a hefty Series B round and made the jump to Nasdaq. And now, it has a late-stage candidate that CEO RA Session II says is just about ready for regulators.
The Dallas-based biotech on Monday unveiled a deal for global rights to TSHA-120 — a gene therapy discovered in the lab of UT Southwestern’s Steven Gray to treat a debilitating neurodegenerative disease called giant axonal neuropathy (GAN). It’s the first gene therapy to be administered in humans intrathecally (into the spinal canal), according to Session, who’s currently lining up an end-of-phase meeting with the FDA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
